# US 2020/0390789 A1 · Methods and materials for treating human immunodeficiency virus infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390789 A1
- Document ID: US20200390789A1
- Status: Published application
- Kind: A1
- Application number: 17/003,818
- Filed: 2020-08-26
- Published: 2020-12-17
- Earliest claimed: 2015-02-23
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: Andrew Badley
- Web page: https://patentgrep.com/patent/US20200390789A1

## CPC

- A61K 31/69: Boron compounds
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/5365: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 38/05: Dipeptides
- A61K 38/2013: {IL-2}
- A61K 38/2086: {IL-13 to IL-16}
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/18: for HIV
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This document provides methods and materials for treating HIV infections. For example, methods and materials for using one or more proteosome inhibitors in combination with one or more other agents to treat HIV infections are provided.

## Claims

### Claim 1

A method for reducing the number of latently HIV infected cells within a human infected with HIV, wherein said method comprises:
(a) administering a proteosome inhibitor to said human, and
(b) administering a combination of anti-retroviral agents to said human.

### Claim 2 (depends on 1)

The method of claim 1, wherein said cells are CD4+ T cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein said proteosome inhibitor is ixazomib or bortezomib.

### Claim 4 (depends on 1)

The method of claim 1, wherein said proteosome inhibitor is ixazomib.

### Claim 5 (depends on 1)

The method of claim 1, wherein said combination comprises an integrase inhibitor, a protease inhibitor, and a reverse transcriptase inhibitor.

### Claim 6 (depends on 5)

The method of claim 5, wherein said integrase inhibitor is raltegravir.

### Claim 7 (depends on 5)

The method of claim 5, wherein said protease inhibitor is darunavir or atazanavir.

### Claim 8 (depends on 5)

The method of claim 5, wherein said reverse transcriptase inhibitor is selected from the group consisting of emtricitabine, rilpivirine, and tenofovir.

### Claim 9 (depends on 1)

The method of claim 1, wherein said method comprises administering a latency reversing agent to said human.

### Claim 10 (depends on 9)

The method of claim 9, wherein said latency reversing agent is selected from the group consisting of an HDAC inhibitor, a phorbol ester, IL-2, and a bromodomain inhibitor.

### Claim 11 (depends on 1)

The method of claim 1, wherein said method comprises administering an immunotherapeutic agent, a vaccine, or a nucleic acid to said human.

### Claim 12 (depends on 11)

The method of claim 11, wherein said method comprises administering an immunotherapeutic agent to said human, wherein said immunotherapeutic agent is IL-15.

### Claim 13 (depends on 11)

The method of claim 11, wherein said method comprises administering a vaccine to said human.

### Claim 14 (depends on 11)

The method of claim 11, wherein said method comprises administering a nucleic acid to said human, wherein said nucleic acid is designed to reduce CCR5 polypeptide expression.
